Litigation Details for In re Novartis and Par Antitrust Litigation (S.D.N.Y. 2018)

« Back to Dashboard

In re Novartis and Par Antitrust Litigation (S.D.N.Y. 2018)

Docket		Date Filed	2018-05-16
Court	District Court, S.D. New York	Date Terminated
Cause	15:1 Antitrust Litigation (Monopolizing Trade)	Assigned To	Alvin K. Hellerstein
Jury Demand	Plaintiff	Referred To
Patents	6,294,197; 6,395,728
Link to Docket	External link to docket

Details for In re Novartis and Par Antitrust Litigation (S.D.N.Y. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-05-16	193	Memorandum & Opinion	of certain follow-on patents (U.S. Patent Nos. 6,294,197 ("the '197 Patent") and 6,395,728…Novartis' patents. Novartis owned U.S. Patent No. 5,399,578 ("the '578 patent), which covered…, 4, 77. The validity of this patent was not challenged. The patent expired on March 21, 20_12, and… to the patent holder, among others, and describe the basis for its position that the patent at issue…, "Novartis"), nearing the end of one patent covering their prescription drug, Exforge, a blood	External link to document

In re Novartis and Par Antitrust Litigation, 1:18-cv-04361-AKH: Litigation Summary and Patent-Entry Analysis

Last updated: October 18, 2026

In re Novartis and Par Antitrust Litigation concerns alleged anticompetitive conduct involving Novartis’s Exforge product, a combination of amlodipine besylate and valsartan, and Par Pharmaceutical’s potential generic entry. The case was filed in the U.S. District Court for the Southern District of New York under Case No. 1:18-cv-04361-AKH before Judge Alvin K. Hellerstein.

The plaintiffs’ core theory is that Novartis and Par used a patent-settlement arrangement to delay generic competition for Exforge. The case is governed by the framework established in FTC v. Actavis, under which a reverse-payment settlement may violate the antitrust laws when the payment is large, unexplained, and associated with delayed generic entry.[1]

What is In re Novartis and Par Antitrust Litigation?

The action is a private antitrust case involving the market for Exforge, an antihypertensive combination product containing amlodipine and valsartan.

The complaint alleges that:

• Novartis held patents and regulatory rights associated with Exforge.
• Par challenged Novartis’s patent position or sought to enter the market with a generic equivalent.
• Novartis and Par resolved their dispute through an agreement that allegedly restricted or postponed Par’s commercial entry.
• The agreement allegedly preserved Novartis’s monopoly revenues and delayed lower-priced generic supply.
• Direct purchasers paid supracompetitive prices during the alleged delay period.

The case is not a biosimilar dispute. Exforge is a small-molecule drug regulated through the abbreviated new drug application, or ANDA, pathway. The central regulatory and competitive issue is generic entry, not interchangeability of a biologic.

Which drug and formulations are involved?

The litigation centers on Exforge, marketed by Novartis as a fixed-dose combination of amlodipine besylate and valsartan.

Product	Active ingredients	Therapeutic use	Regulatory pathway for competition
Exforge	Amlodipine besylate and valsartan	Hypertension	ANDA generic pathway
Generic Exforge	Amlodipine besylate and valsartan	Hypertension	Abbreviated new drug application
Exforge HCT	Amlodipine, valsartan and hydrochlorothiazide	Hypertension	Separate product and patent analysis

The principal litigation theory concerns the Exforge combination rather than Novartis’s broader hypertension portfolio. Exforge HCT has a third active ingredient, hydrochlorothiazide, and should not automatically be treated as identical to Exforge for patent, Orange Book, or market-share analysis.

What antitrust conduct did the plaintiffs allege?

The plaintiffs allege a reverse-payment or pay-for-delay arrangement. In a conventional patent settlement, the generic company may agree to enter before patent expiration in exchange for the branded company ending or resolving its infringement claims. The arrangement becomes antitrust-sensitive when the branded company provides value to the generic company in exchange for delayed entry.

The alleged economic value can take several forms:

1. Cash or other direct payments.
2. A license allowing entry at a later date.
3. An agreement by the brand company not to launch an authorized generic.
4. Business arrangements that reduce the generic company’s competitive risk.
5. Side agreements that transfer commercial value outside the patent settlement itself.

The Supreme Court held in Actavis that a reverse payment is not automatically lawful merely because it resolves patent litigation. Courts must evaluate whether the payment reflects a legitimate settlement or instead reflects compensation for abandoning or delaying competition.[1]

The Second Circuit has applied Actavis to settlements involving alleged consideration beyond a direct cash payment. The relevant inquiry is the economic substance of the arrangement, not the label assigned by the contracting parties.[2]

What is the procedural history of the case?

The action was filed in 2018 in the Southern District of New York as Case No. 1:18-cv-04361-AKH. The case was assigned to Judge Alvin K. Hellerstein.

The litigation follows the standard sequence for pharmaceutical antitrust actions:

Procedural issue	Relevance
Complaint	Alleged that Novartis and Par delayed generic Exforge competition
Defendants’ response	Challenged the sufficiency of the antitrust claims and the characterization of the settlement
Discovery	Focused on settlement negotiations, expected generic launch timing, patent strength and commercial value
Class and damages issues	Concerned whether direct purchasers could establish common injury and overcharge
Final disposition	Controlled by the federal docket and any settlement or dismissal orders entered in the action

The case should be distinguished from a patent-infringement action. The operative question is not whether Novartis’s patents were valid or infringed in isolation. The question is whether the parties used the patent dispute and its settlement to restrict competition beyond what the patent rights could lawfully justify.

What role did patent litigation play?

Patent litigation was the mechanism through which the parties structured their commercial relationship. In pharmaceutical antitrust cases, the patent dispute is often relevant for three reasons.

First, patent strength affects the expected value of generic entry. A weak patent can make delayed entry more valuable to the brand company because the generic may have a substantial probability of entering before expiration or prevailing in litigation.

Second, the expected entry date affects damages. If Par could have launched earlier absent the settlement, plaintiffs may claim overcharges for the period between the hypothetical launch date and the actual launch date.

Third, patent scope limits the legal value of a settlement. A brand company may settle by granting entry before patent expiration, but an agreement that extends exclusivity beyond the lawful exclusionary scope of the patent can create antitrust exposure.

The complaint’s theory therefore depends on a counterfactual: when would Par have entered the market absent the challenged agreement?

When would generic Exforge have entered without the alleged agreement?

The entry date is a central damages and liability issue. The relevant analysis requires reconstruction of:

• Par’s ANDA filing date.
• Any Paragraph IV certification.
• The date Novartis initiated patent litigation.
• The statutory 30-month stay, if applicable.
• The strength of the asserted patents.
• The contractual entry date.
• The date of actual commercial launch.
• Whether an authorized generic was commercially available.
• Whether other generic manufacturers entered during the same period.

A Paragraph IV certification is a statutory assertion that a listed patent is invalid, unenforceable or not infringed. It can trigger patent litigation and, in some circumstances, provide the first ANDA filer with 180 days of generic exclusivity under the Hatch-Waxman Act.[3]

The antitrust significance of a Paragraph IV challenge depends on the facts. Filing a Paragraph IV certification is not itself proof that generic entry would have occurred. Plaintiffs must generally show that the generic had a plausible path to earlier entry and that the settlement materially delayed that path.

Did the case involve a no-authorized-generic agreement?

No-authorized-generic provisions are important in reverse-payment analysis because they can transfer substantial value without an express cash payment.

An authorized generic is a brand manufacturer’s product sold as a generic, usually through a subsidiary or licensing arrangement. A promise by the brand company not to launch an authorized generic can increase the first-filer’s expected revenues during the 180-day exclusivity period.

For a generic company, the value of a no-authorized-generic commitment can include:

• Higher prices during generic exclusivity.
• Greater market share.
• Reduced price erosion.
• Higher settlement value.
• Lower competitive pressure after launch.

If the Novartis-Par agreement included such a restriction, plaintiffs could argue that the commitment was an economically significant payment. The defendants would likely argue that the arrangement was part of a legitimate resolution of patent uncertainty and did not compensate Par for abandoning a viable challenge.

The court’s analysis would turn on the size and explanation of the alleged value, the strength of Novartis’s patent claims, and the expected litigation outcome under Actavis.[1]

What is the Orange Book status of Exforge?

The FDA’s Orange Book identifies patents submitted by sponsors for approved drug products and therapeutic uses. Orange Book listing is important because listed patents can support a statutory patent certification and trigger Hatch-Waxman litigation.

For Exforge, the relevant review should distinguish:

• Patents covering the active ingredients.
• Combination-product patents.
• Formulation patents.
• Use patents.
• Patents covering Exforge HCT rather than Exforge.
• Patents that expired before the alleged generic-entry period.
• Patents delisted, disclaimed or otherwise excluded from the operative dispute.

Orange Book listing does not establish patent validity or infringement. It provides the regulatory mechanism for patent certification and litigation. The antitrust case requires a separate evaluation of whether the patents created a legitimate exclusionary position and whether the settlement exceeded that position.

How strong was Novartis’s patent estate?

The estate should be assessed as moderate rather than treated as automatically strong solely because patents were listed or litigation was filed.

Relevant strength factors include:

Factor	Antitrust significance
Patent expiration	Defines the maximum ordinary exclusion period
Claim scope	Determines whether the patent reached generic Exforge
Validity vulnerabilities	Affect expected litigation outcomes
Prior-art record	Influences the probability of invalidity
Infringement case	Determines whether Par could enter without infringement liability
Patent-family overlap	May affect the duration and practical value of exclusion
Regulatory exclusivity	Can delay approval independently of patent rights

A strong patent can justify a settlement that permits entry before expiration. It does not automatically immunize a settlement containing a large unexplained transfer of value. Conversely, a weak patent may increase the inference that payment was made to avoid competition rather than to resolve a legitimate dispute.

What generic-entry risks did Novartis face?

Novartis faced several potential risks if Par or another ANDA applicant entered the Exforge market:

1. Immediate price erosion.
2. Loss of pharmacy and wholesaler volume.
3. Reduced market share in the fixed-dose combination segment.
4. Possible acceleration of additional generic launches.
5. Loss of revenue from the branded product.
6. Reduced leverage in related hypertension products.

Generic entry is usually more damaging when the product has high prescription volume, limited therapeutic differentiation and substantial pharmacy substitution. The commercial exposure depends on the date of entry, the number of approved ANDAs, the presence of an authorized generic and the structure of payer reimbursement.

Which companies challenged Novartis’s Exforge position?

Par is the defendant generic manufacturer identified in the case title. Other ANDA applicants may have been relevant to the broader competitive landscape, but the litigation’s central alleged agreement is between Novartis and Par.

The key competitive comparison is therefore:

Company	Role	Litigation significance
Novartis	Brand manufacturer	Held the Exforge commercial position and asserted patent rights
Par Pharmaceutical	Generic manufacturer	Alleged counterparty to the settlement and potential entrant
Other ANDA applicants	Potential competitors	Relevant to entry timing, damages and market definition
Wholesalers and pharmacies	Distribution channel	Potential direct-purchaser or downstream market participants

Does the case create biosimilar risk?

No. Exforge is a small-molecule combination drug, not a biologic. The applicable competitive risks are:

• ANDA approval.
• Paragraph IV patent challenges.
• 180-day generic exclusivity.
• Authorized-generic competition.
• Formulation or combination-product patents.
• State and federal antitrust claims.

Biosimilar approval under the Biologics Price Competition and Innovation Act is not relevant to the Exforge dispute.

What litigation and settlement issues matter most?

The principal litigation issues are:

• Whether Novartis transferred value to Par.
• Whether the transfer was large and unexplained.
• Whether the settlement delayed entry beyond a commercially reasonable date.
• Whether Novartis’s patents had meaningful litigation strength.
• Whether the agreement restricted authorized-generic competition.
• Whether plaintiffs can prove class-wide injury.
• Whether direct purchasers can quantify overcharges.
• Whether the alleged delay caused antitrust injury rather than merely reflecting patent exclusivity.

Any settlement would typically require evaluation of class certification, claims administration, release scope, attorney fees and the relationship between the settlement amount and estimated overcharges. A settlement would not constitute an admission of liability unless the agreement expressly provided otherwise.

How does this case compare with other pay-for-delay cases?

The case belongs to the same legal category as other pharmaceutical antitrust actions involving patent settlements and delayed generic entry. Its principal benchmark is Actavis.

The comparison is straightforward:

Issue	Novartis and Par	Actavis framework
Product	Small-molecule combination drug	Small-molecule pharmaceutical product
Alleged conduct	Settlement restricting generic competition	Reverse payment and delayed entry
Key question	Whether Par received compensating value	Whether payment was large and unexplained
Regulatory pathway	Hatch-Waxman ANDA	Hatch-Waxman ANDA
Main damages issue	Earlier hypothetical generic launch	Overcharges during delayed-entry period

The case does not establish that every patent settlement involving an agreed generic-entry date violates antitrust law. Liability requires a fact-specific analysis of payment, patent strength, entry timing and competitive effect.

Key Takeaways

• In re Novartis and Par Antitrust Litigation is a private antitrust action concerning alleged delayed generic entry for Exforge.
• The case is distinct from patent infringement litigation, although the patent dispute supplied the commercial setting.
• The relevant legal framework is FTC v. Actavis and subsequent Second Circuit authority.
• Any no-authorized-generic commitment could be treated as an economically significant transfer of value.
• The central damages question is when Par would have entered absent the challenged agreement.
• Exforge is a small-molecule drug subject to the ANDA pathway, not a biosimilar product.
• Orange Book listings establish a regulatory patent-certification mechanism, not patent validity.
• Patent strength, settlement value, generic-entry timing and proof of overcharge are the principal decision variables.

FAQs About In re Novartis and Par Antitrust Litigation

What court handled In re Novartis and Par Antitrust Litigation?

The case was filed in the U.S. District Court for the Southern District of New York under Case No. 1:18-cv-04361-AKH and assigned to Judge Alvin K. Hellerstein.

What product is at issue in the Novartis-Par litigation?

The litigation concerns Exforge, a fixed-dose combination of amlodipine besylate and valsartan used to treat hypertension.

Is the Novartis-Par case a patent case or an antitrust case?

It is an antitrust case. The underlying patent dispute is relevant because the parties allegedly used a patent settlement to delay generic competition.

What is the significance of a no-authorized-generic provision?

A no-authorized-generic provision can give the generic company substantial economic value by protecting its market share and pricing during generic exclusivity. Under Actavis, that value may be examined as a reverse payment.

Does the litigation affect biosimilar competition?

No. Exforge is a small-molecule product. The relevant competitive pathway is generic approval through an ANDA and potential Paragraph IV patent litigation.

References

1. Federal Trade Commission v. Actavis, Inc., 570 U.S. 136 (2013).

2. In re Aggrenox Antitrust Litigation, 2019 WL 5691120 (S.D.N.Y. Nov. 4, 2019).

3. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

4. In re Novartis and Par Antitrust Litigation, No. 1:18-cv-04361-AKH, U.S. District Court for the Southern District of New York, docket materials.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.